Article Text

This article has a correction. Please see:

other Versions

PDF
Research letter
Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA
  1. J R Stradling1,
  2. S E Craig1,
  3. M Kohler1,2,
  4. D Nicoll1,
  5. L Ayers3,
  6. A J Nunn4,
  7. D J Bratton4
  1. 1Oxford Centre for Respiratory Medicine and Oxford Biomedical Research Centre, Churchill Hospital Campus, Oxford University Hospitals NHS Trust, Oxford, UK
  2. 2Sleep Disorders Centre and Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland
  3. 3Department of Clinical Immunology, Churchill Hospital Campus, Oxford University Hospitals NHS Trust, Oxford, UK
  4. 4MRC Clinical Trials Unit at UCL, Aviation House, London, UK
  1. Correspondence to Professor John R Stradling, Oxford Centre for Respiratory Medicine and Oxford Biomedical Research Centre, Churchill Hospital Campus, Oxford University, Oxford OX3 7LJ, UK; john.stradling{at}orh.nhs.uk

Abstract

ABSTRACT The Multi-centre Obstructive Sleep Apnoea Interventional Cardiovascular (MOSAIC) trial compared 6 months of CPAP therapy, versus no CPAP, in 391 patients with minimally symptomatic obstructive sleep apnoea (OSA). We now report some exploratory outcomes, markers of systemic inflammation (interleukin 6 (IL-6), IL-10, C reactive protein, tumour necrosis factor). We found no consistent changes (all p values >0.13).

Trial registration number: ISRCTN 34164388.

  • Sleep apnoea
  • Cytokine Biology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd and British Thoracic Society